Abstract：
OBJECTIVE: This study aims to investigate the potential of stromal vascular fraction (SVF) for peripheral nerve regeneration.
METHODS: A scoping review of Scopus and PubMed databases was conducted. Inclusion criteria were human or animal studies exploring the use of SVF for peripheral nerve regeneration. Studies were categorized by assessed outcomes: pain assessment, neural integrity, muscle recovery, and functional recovery. Level of evidence and study quality were assessed.
RESULTS: Nine studies met the inclusion criteria. SVF injection in humans with trigeminal neuropathic pain reduced pain scores from 7.5 ± 1.58 to 4.3 ± 3.28. SVF injection improved sensation in humans with leprosy neuropathy. Repairing transected rat sciatic nerves with SVF-coated nerve autografts improved wet muscle weight ratios (0.65 ± 0.11 vs 0.55 ± 0.06) and sciatic functional index (SFI) scores (-68.2 ± 9.2 vs -72.5 ± 8.9). Repairing transected rat sciatic nerves with SVF-coated conduits increased the ratio of gastrocnemius muscle weights (RGMW) (7-10% improvement), myelinated fibers (1,605 ± 806.2 vs 543.6 ± 478.66), and myelin thickness (5-20% increase). Repairing transected rat facial nerves with SVF-coated conduits improved whisker motion (9.22° ± 0.65° vs 1.90° ± 0.84°) and myelin thickness (0.57 μm ± 0.17 vs 0.45 μm ± 0.14 μm). Repairing transected rat sciatic nerves with SVF-coated nerve allografts improved RGMW (85 vs 50%), SFI scores (-20 to -10 vs -40 to -30), and Basso, Beatie, and Bresnahan locomotor scores (18 vs 15). All metrics mentioned above were statistically significant. The human studies were level 4 evidence due to being case series, while animal studies were the lowest level of evidence.
CONCLUSIONS: Despite initial promising results, the low-level evidence from the included studies warrants further investigation.
METHODS: A scoping review of Scopus and PubMed databases was conducted. Inclusion criteria were human or animal studies exploring the use of SVF for peripheral nerve regeneration. Studies were categorized by assessed outcomes: pain assessment, neural integrity, muscle recovery, and functional recovery. Level of evidence and study quality were assessed.
RESULTS: Nine studies met the inclusion criteria. SVF injection in humans with trigeminal neuropathic pain reduced pain scores from 7.5 ± 1.58 to 4.3 ± 3.28. SVF injection improved sensation in humans with leprosy neuropathy. Repairing transected rat sciatic nerves with SVF-coated nerve autografts improved wet muscle weight ratios (0.65 ± 0.11 vs 0.55 ± 0.06) and sciatic functional index (SFI) scores (-68.2 ± 9.2 vs -72.5 ± 8.9). Repairing transected rat sciatic nerves with SVF-coated conduits increased the ratio of gastrocnemius muscle weights (RGMW) (7-10% improvement), myelinated fibers (1,605 ± 806.2 vs 543.6 ± 478.66), and myelin thickness (5-20% increase). Repairing transected rat facial nerves with SVF-coated conduits improved whisker motion (9.22° ± 0.65° vs 1.90° ± 0.84°) and myelin thickness (0.57 μm ± 0.17 vs 0.45 μm ± 0.14 μm). Repairing transected rat sciatic nerves with SVF-coated nerve allografts improved RGMW (85 vs 50%), SFI scores (-20 to -10 vs -40 to -30), and Basso, Beatie, and Bresnahan locomotor scores (18 vs 15). All metrics mentioned above were statistically significant. The human studies were level 4 evidence due to being case series, while animal studies were the lowest level of evidence.
CONCLUSIONS: Despite initial promising results, the low-level evidence from the included studies warrants further investigation.
摘要：
目的：本研究旨在探讨基质血管分数（SVF）在周围神经再生中的潜力。
方法：对Scopus和PubMed数据库进行范围审查。纳入标准是探索SVF用于周围神经再生的人或动物研究。研究按评估结果分类：疼痛评估，神经完整性,肌肉恢复,功能恢复。评估证据水平和研究质量。
结果：9项研究符合纳入标准。在患有三叉神经性疼痛的人中注射SVF将疼痛评分从7.5±1.58降低至4.3±3.28。SVF注射改善了麻风神经病患者的感觉。用SVF涂层的自体神经移植物修复横断的大鼠坐骨神经可改善湿重比（0.65±0.11vs0.55±0.06）和坐骨神经功能指数（SFI）评分（-68.2±9.2vs-72.5±8.9）。用SVF涂层导管修复横断的大鼠坐骨神经增加了相对腓肠肌重量（RGMW）（7-10％改善），有髓纤维（1,605±806.2vs543.6±478.66），和髓鞘厚度（增加5-20％）。用SVF涂层导管修复横断的大鼠面神经可改善晶须运动（9.22°±0.65°vs1.90°±0.84°）和髓鞘厚度（0.57μm±0.17vs0.45μm±0.14μm）。用SVF涂层同种异体神经移植修复横断的大鼠坐骨神经可改善RGMW（85vs50％），SFI得分（-20到-10vs-40到-30），还有巴索,Beatie,和Bresnahan运动分数（18vs15）。上述所有指标均具有统计学意义。由于是病例系列，人体研究是4级证据，而动物研究是最低水平的证据。
结论：尽管最初的结果很有希望，纳入研究的低水平证据值得进一步调查.
方法：对Scopus和PubMed数据库进行范围审查。纳入标准是探索SVF用于周围神经再生的人或动物研究。研究按评估结果分类：疼痛评估，神经完整性,肌肉恢复,功能恢复。评估证据水平和研究质量。
结果：9项研究符合纳入标准。在患有三叉神经性疼痛的人中注射SVF将疼痛评分从7.5±1.58降低至4.3±3.28。SVF注射改善了麻风神经病患者的感觉。用SVF涂层的自体神经移植物修复横断的大鼠坐骨神经可改善湿重比（0.65±0.11vs0.55±0.06）和坐骨神经功能指数（SFI）评分（-68.2±9.2vs-72.5±8.9）。用SVF涂层导管修复横断的大鼠坐骨神经增加了相对腓肠肌重量（RGMW）（7-10％改善），有髓纤维（1,605±806.2vs543.6±478.66），和髓鞘厚度（增加5-20％）。用SVF涂层导管修复横断的大鼠面神经可改善晶须运动（9.22°±0.65°vs1.90°±0.84°）和髓鞘厚度（0.57μm±0.17vs0.45μm±0.14μm）。用SVF涂层同种异体神经移植修复横断的大鼠坐骨神经可改善RGMW（85vs50％），SFI得分（-20到-10vs-40到-30），还有巴索,Beatie,和Bresnahan运动分数（18vs15）。上述所有指标均具有统计学意义。由于是病例系列，人体研究是4级证据，而动物研究是最低水平的证据。
结论：尽管最初的结果很有希望，纳入研究的低水平证据值得进一步调查.
